Denise Damek, MD
Professor, Neurology

Professor of Neurology
Clinic (720) 848-0300
Print Profile
Email Profile
Featured Provider Photo

Gender: Female
Languages: English
Department, Section/Division: Neurology
Neurosurgery

Practice Locations

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
More providers at this location

UCHealth Brain and Spine Tumor Multidisciplinary Clinic - Anschutz Medical Campus
1665 Aurora Court, Anschutz Cancer Pavilion, 2nd Floor, Suite 2004
Aurora, CO 80045
720-848-0300
More providers at this location

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080
More providers at this location

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Neurology, Board Certification (1998)
  • Neurology - Neuro-Oncology
  • United Council for Neurologic Subspecialties, Specialized Training (2008)
Conditions & Treatments
  • Brain and Nervous System
  • Brain Tumors
  • Spine Diseases and Conditions
  • Cancers

Education & Training

Medical Schools:
  • MD, University of Texas Medical School at Houston (1992)

Undergraduate Schools:
  • BS, University of Texas–Austin (TX) (1988)

Internships:
  • College of Medicine, Mayo Clinic (Rochester) Program (1993)

Residency Program:
  • College of Medicine, Mayo Clinic (Rochester) Program, Psychiatry (1996)

Fellowships:
  • Massachusetts General Hospital Program, Neuro-Oncology (1998)

Professional Memberships

  • American Academy of Neurology, Member
  • American Medical Association, Member
  • Society for Neuro-Oncology, Member

Research & Grants

Grants
  • ABT-414 alone or ABT-414 plus temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group (2016)
    AbbVie, $165350
  • A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (2016)
    Tocagen Inc., $150422
  • Immunocellular Therapeutics Ltd. ICT-107-301. A phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy (2015)
    Immunocellular Therapeutics Ltd, $150422
  • Chart Review Study of Patients who Received IRESSA as Part of a Clinical Access Program (ICAP) in the United States (2015)
    AstraZeneca, $17640
  • A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (2014)
    Bristol-Myers Squibb, $116662

Information for Referring Providers

Clinical Interests for Referring Providers
Neuro-oncology including: Diagnosis and Treatment of Primary and Metastic Tumors of Brain and Spinal Cord, Paraneoplastic Disorders and Other Neurologic Complications of Systemic Cancer, CNS Lymphoma, Radiation Necrosis involving Nervous System


Clinic Phone: (720) 848-0300

CV Damek_CV_2023.pdf